• Anixa Biosciences' CEO Amit Kumar made recent significant insider purchases, acquiring thousands of shares on July 27 and July 24.
  • The stock is rebounding today, trading at $3.66 (5.8% up), following a period of volatility and a recent "Strong Buy" upgrade with an $8.50 price target from Zacks Research.
  • This fresh insider confidence, coupled with positive oncology pipeline validation, provides a company-specific catalyst for today's upward movement.